1. Nabil S, Samman N. Risk factors for osteoradionecrosis after head and neck radiation: a systematic review. Or Surg or Med or Pa. 2012; 113(1): 54-69. DOI: 10.1016/j.tripleo.2011.07.042.
2. Reuther T, Schuster T, Mende U, Kubler A. Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients - a report of a thirty year retrospective review. Int J Oral Max Surg. 2003; 32(3): 289-95. DOI: 10.1054/ijom.2002.0332.
3. Bettoni J, Olivetto M, Duisit J, et al. The value of reconstructive surgery in the management of refractory jaw osteoradionecrosis: a single-center 10-year experience. Int J Oral Maxillofac Surg. 2019; 48(11): 1398-404. DOI: 10.1016/j.ijom.2019.06.007.
4. Rice N, Polyzois I, Ekanayake K, Omer O, Stassen LF. The management of osteoradionecrosis of the jaws--a review. Surgeon. 2015; 13(2): 101-9. DOI: 10.1016/j.surge.2014.07.003.
5. Chrcanovic BR, Reher P, Sousa AA, Harris M. Osteoradionecrosis of the jaws--a current overview--Part 2: dental management and therapeutic options for treatment. Oral Maxillofac Surg. 2010; 14(2): 81-95. DOI: 10.1007/s10006-010-0205-1.
6. Epstein JB, Wong FL, Stevenson-Moore P. Osteoradionecrosis: clinical experience and a proposal for classification. Journal of oral and maxillofacial surgery. 1987; 45(2): 104-10. DOI: 10.1016/0278-2391(87)90399-5.
7. Marx RE. Osteoradionecrosis: a new concept of its pathophysiology. Journal of oral and maxillofacial surgery. 1983; 41(5): 283-8. DOI: 10.1016/0278-2391(83)90294-x.
8. Chronopoulos A, Zarra T, Ehrenfeld M, Otto S. Osteoradionecrosis of the jaws: definition, epidemiology, staging and clinical and radiological findings. A concise review. Int Dent. J. 2018; 68(1): 22-30. DOI: 10.1111/idj.12318.
9. Owosho AA, Tsai CJ, Lee RS, et al. The prevalence and risk factors associated with osteoradionecrosis of the jaw in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT): The Memorial Sloan Kettering Cancer Center experience. Oral Oncol. 2017; 64: 44-51. DOI: 10.1016/j.oraloncology.2016.11.015.
10. Raguse JD, Hossamo J, Tinhofer I, et al. Patient and treatment-related risk factors for osteoradionecrosis of the jaw in patients with head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016; 121(3): 215-21 e1. DOI: 10.1016/j.oooo.2015.10.006.
11. Wehrhan F, Weber M, Neukam FW, Geppert CI, Kesting M, Preidl RHM. Fluorescence-guided bone resection: A histological analysis in medication-related osteonecrosis of the jaw. J Cranio Maxill Surg. 2019; 47(10): 1600-7. DOI: 10.1016/j.jcms.2019.07.012.
12. Tsuchimochi M, Kurabayashi T. Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (1), role of imaging in drug-related osteonecrosis of the jaw: An up-to-date review (secondary publication). Jpn Dent Sci Rev. 2019; 55(1): 1-4. DOI: 10.1016/j.jdsr.2018.11.004.
13. Lapa C, Linz C, Bluemel C, et al. Three-phase bone scintigraphy for imaging osteoradionecrosis of the jaw. Clin Nucl Med. 2014; 39(1): 21-5. DOI: 10.1097/RLU.0000000000000296.
14. Pautke C, Bauer F, Tischer T, et al. Fluorescence-Guided Bone Resection in Bisphosphonate-Associated Osteonecrosis of the Jaws. Journal of Oral and Maxillofacial Surgery. 2009; 67(3): 471-6. DOI: 10.1016/j.joms.2008.09.037.
15. Pautke C, Bauer F, Bissinger O, et al. Tetracycline Bone Fluorescence: A Valuable Marker for Osteonecrosis Characterization and Therapy. Journal of Oral and Maxillofacial Surgery. 2010; 68(1): 125-9. DOI: 10.1016/j.joms.2009.05.442.
16. Pautke C, Bauer F, Otto S, et al. Fluorescence-Guided Bone Resection in Bisphosphonate-Related Osteonecrosis of the Jaws: First Clinical Results of a Prospective Pilot Study. Journal of Oral and Maxillofacial Surgery. 2011; 69(1): 84-91. DOI: 10.1016/j.joms.2010.07.014.
17. Otto S, Baumann S, Ehrenfeld M, Pautke C. Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery. 2013; 41(7): 694-8. DOI: 10.1016/j.jcms.2013.05.038.
18. Otto S, Ristow O, Pache C, et al. Fluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw: A prospective cohort study. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery. 2016; 44(8): 1073-80. DOI: 10.1016/j.pdpdt.2020.102003.
19. Assaf AT, Zrnc TA, Riecke B, et al. Intraoperative efficiency of fluorescence imaging by Visually Enhanced Lesion Scope (VELscope (R)) in patients with bisphosphonate related osteonecrosis of the jaw (BRONJ). J Cranio Maxill Surg. 2014; 42(5): E157-E64. DOI: 10.1016/j.jcms.2013.07.014.
20. Otto S, Schnödt EM, Haidari S, et al. Autofluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw (MRONJ): a retrospective single-center study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020. DOI: 10.1016/j.oooo.2020.10.018.
21. Ristow O, Pautke C. Auto-fluorescence of the bone and its use for delineation of bone necrosis. Int J Oral Max Surg. 2014; 43(11): 1391-3. DOI: 10.1016/j.ijom.2014.07.017.
22. Giovannacci I, Meleti M, Corradi D, Vescovi P. Clinical Differences in Autofluorescence Between Viable and Nonvital Bone: A Case Report With Histopathologic Evaluation Performed on Medication-Related Osteonecrosis of the Jaws. Journal of Oral and Maxillofacial Surgery. 2017; 75(6): 1216-22. DOI: 10.1016/j.joms.2016.12.011.
23. Giovannacci I, Meleti M, Manfredi M, et al. Autofluorescence as indicator for detecting the surgical margins of medication-related osteonecrosis of the jaws. Minerva Stomatologica. 2016; 65(4): 248-52.
24. Vescovi P, Giovannacci I, Otto S, et al. Medication-Related Osteonecrosis of the Jaw: An Autofluorescence-Guided Surgical Approach Performed with Er:YAG Laser. Photomedicine and laser surgery. 2015; 33(8): 437-42. DOI: 10.1089/pho.2015.3927.
25. Ristow O, Nehrbass D, Zeiter S, et al. Differences between auto-fluorescence and tetracycline-fluorescence in medication-related osteonecrosis of the jaw-a preclinical proof of concept study in the mini-pig. Clin Oral Invest. 2020; 24(12): 4625-37. DOI: 10.1007/s00784-020-03332-2.
26. Notani K, Yamazaki Y, Kitada H, et al. Management of mandibular osteoradionecrosis corresponding to the severity of osteoradionecrosis and the method of radiotherapy. Head Neck-J Sci Spec. 2003; 25(3): 181-6. DOI: 10.1002/hed.10171.
27. Tocaciu S, Breik O. The need for more robust research on the role of pentoxifylline and tocopherol in the management of osteoradionecrosis of the jaws. Int J Oral Maxillofac Surg. 2020; 49(4): 544-5. DOI: 10.1016/j.ijom.2019.08.021.
28. McCaul JA. Pharmacologic modalities in the treatment of osteoradionecrosis of the jaw. Oral Maxillofac Surg Clin North Am. 2014; 26(2): 247-52. DOI: 10.1016/j.coms.2014.02.002.
29. Annane D, Depondt J, Aubert P, et al. Hyperbaric oxygen therapy for radionecrosis of the jaw: A randomized, placebo-controlled, double-blind trial from the ORN96 Study Group. J Clin Oncol. 2004; 22(24): 4893-900. DOI: 10.1200/JCO.2004.09.006.
30. Martos-Fernandez M, Saez-Barba M, Lopez-Lopez J, Estrugo-Devesa A, Balibrea-Del-Castillo JM, Bescos-Atin C. Pentoxifylline, tocopherol, and clodronate for the treatment of mandibular osteoradionecrosis: a systematic review. Or Surg or Med or Pa. 2018; 125(5): 431-9. DOI: 10.1016/j.oooo.2018.02.004
31. Oh HK, Chambers MS, Martin JW, Lim HJ, Park HJ. Osteoradionecrosis of the mandible: treatment outcomes and factors influencing the progress of osteoradionecrosis. J Oral Maxillofac Surg. 2009; 67(7): 1378-86. DOI: 10.1016/j.joms.2009.02.008.
32. Chrcanovic BR, Reher P, Sousa AA, Harris M. Osteoradionecrosis of the jaws--a current overview--part 1: Physiopathology and risk and predisposing factors. Oral Maxillofac Surg. 2010; 14(1): 3-16. DOI: 10.1007/s10006-009-0198-9.
33. Ristow O, Otto S, Geiß C, et al. Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. Int J Oral Maxillofac Surg. 2017; 46(2): 157-66. DOI: 10.1016/j.ijom.2016.10.008.
34. Grisar K, Schol M, Schoenaers J, et al. Osteoradionecrosis and medication-related osteonecrosis of the jaw: similarities and differences. Int J Oral Maxillofac Surg. 2016; 45(12): 1592-9. DOI: 10.1016/j.ijom.2016.06.016.
35. Bagan JV, Jiménez Y, Hernández S, et al. Osteonecrosis of the jaws by intravenous bisphosphonates and osteoradionecrosis: a comparative study. Medicina oral, patologia oral y cirugia bucal. 2009; 14(12): e616-9. DOI: 10.4317/medoral.14.e616.
36. Akashi M, Wanifuchi S, Iwata E, et al. Differences between osteoradionecrosis and medication-related osteonecrosis of the jaw. Oral Maxillofac Surg. 2018; 22(1): 59-63. DOI: 10.1007/s10006-017-0667-5.
37. Sathasivam HP, Davies GR, Boyd NM. Predictive factors for osteoradionecrosis of the jaws: A retrospective study. Head Neck. 2018; 40(1): 46-54. DOI: 10.1002/hed.24907.
38. Kojima Y, Yanamoto S, Umeda M, et al. Relationship between dental status and development of osteoradionecrosis of the jaw: a multicenter retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017; 124(2): 139-45. DOI: 10.1016/j.oooo.2017.04.012.